Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Total Liabilities
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has total liabilities worth CN¥1.00 Billion CNY (≈ $146.94 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Jiangsu Nhwa Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Jiangsu Nhwa Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Jiangsu Nhwa Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YUNDA Holding Co Ltd
SHE:002120
|
China | CN¥15.66 Billion |
|
FangDa Carbon New Material Co Ltd
SHG:600516
|
China | CN¥3.06 Billion |
|
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
|
China | CN¥14.45 Billion |
|
Enaex S.A
SN:ENAEX
|
Chile | CL$1.12 Billion |
|
LivaNova PLC
NASDAQ:LIVN
|
USA | $1.40 Billion |
|
Sprott Inc.
TO:SII
|
Canada | CA$217.31 Million |
|
Huber+suhner AG
SW:HUBN
|
Switzerland | CHF199.76 Million |
|
China Petroleum Engineering Corp
SHG:600339
|
China | CN¥97.35 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jiangsu Nhwa Pharmaceutical Co Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Nhwa Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual total liabilities of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.17 Billion ≈ $170.69 Million |
+27.06% |
| 2023-12-31 | CN¥918.09 Million ≈ $134.35 Million |
+2.35% |
| 2022-12-31 | CN¥896.99 Million ≈ $131.26 Million |
+13.05% |
| 2021-12-31 | CN¥793.45 Million ≈ $116.11 Million |
+23.41% |
| 2020-12-31 | CN¥642.94 Million ≈ $94.08 Million |
+7.75% |
| 2019-12-31 | CN¥596.68 Million ≈ $87.31 Million |
-44.48% |
| 2018-12-31 | CN¥1.07 Billion ≈ $157.26 Million |
+27.90% |
| 2017-12-31 | CN¥840.24 Million ≈ $122.95 Million |
-1.26% |
| 2016-12-31 | CN¥850.97 Million ≈ $124.52 Million |
+17.60% |
| 2015-12-31 | CN¥723.60 Million ≈ $105.89 Million |
-16.21% |
| 2014-12-31 | CN¥863.61 Million ≈ $126.37 Million |
+18.28% |
| 2013-12-31 | CN¥730.13 Million ≈ $106.84 Million |
+10.22% |
| 2012-12-31 | CN¥662.41 Million ≈ $96.93 Million |
+23.22% |
| 2011-12-31 | CN¥537.59 Million ≈ $78.67 Million |
+9.32% |
| 2010-12-31 | CN¥491.74 Million ≈ $71.96 Million |
+27.83% |
| 2009-12-31 | CN¥384.68 Million ≈ $56.29 Million |
-0.25% |
| 2008-12-31 | CN¥385.66 Million ≈ $56.43 Million |
-13.22% |
| 2007-12-31 | CN¥444.39 Million ≈ $65.03 Million |
+16.44% |
| 2006-12-31 | CN¥381.63 Million ≈ $55.85 Million |
+6.86% |
| 2005-12-31 | CN¥357.12 Million ≈ $52.26 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more